Hypothyroidism | No hypothyroidism | p-value | |
Demographics | |||
Patients | 538 | 3284 | |
Age years¶ | 45.1±12.5 | 43.1±13.7 | 0.001 |
Duration of disease years¶ | 12.3±10.8 | 11.6±10.9 | 0.136 |
Women | 486/538 (90) | 2326/3284 (71) | <0.001 |
Race | |||
African American | 41/530 (8) | 667/3222 (21) | <0.001 |
White | 480/530 (91) | 2521/3222 (78) | <0.001 |
Other races+ | 10/530 (2) | 74/3222 (2) | 0.55 |
Healthcare insurance | |||
Private health insurance | 332/531 (62.5) | 1816/3256 (56) | 0.004 |
Government insurance | 211/531 (40) | 1078/3256 (33) | 0.003 |
No health insurance | 55/531 (10) | 621/3256 (19) | <0.001 |
Graduated college or university | 284/473 (60) | 1394/2594 (54) | 0.01 |
Income USD | 0.50 | ||
<35000 | 127/442 (29) | 656/2513 (26) | |
35000–99999 | 197/442 (44.5) | 1173/2513 (47) | |
>100000 | 118/442 (26.5) | 684/2513 (27) | |
Healthcare providers seen before sarcoidosis diagnosis was made§ | |||
Endocrinologist | 115/538 (21) | 241/3284 (7) | <0.001 |
Primary care provider | 436/538 (81) | 2623/3284 (80) | 0.53 |
Other specialists | 451/538 (83) | 2569/3284 (78) | 0.003 |
Family history of sarcoidosis | 81/446 (18) | 476/2707 (18) | 0.77 |
Ever admitted to hospital in relation to sarcoidosis | 185/498 (37) | 1158/2995 (39) | 0.52 |
Sarcoidosis-specific therapyƒ | |||
Steroids | 416/536 (78) | 2356/3262 (72) | 0.009 |
Cytotoxic agents | 254/382 (66.5) | 1339/2076 (64.5) | 0.45 |
Tumour necrosis factor inhibitors | 79/312 (25) | 376/1712 (22) | 0.19 |
Others | 38/291 (13) | 142/1616 (9) | 0.007 |
Data are presented as n, mean±sd or n/N total (%), unless otherwise stated. #: Missing values were excluded for each variable. ¶: Age when the diagnosis of sarcoidosis was made or was extremely likely is reported here. Duration is based on time difference in years between age at time of diagnosis and age at time of survey answering. +: Other races include American Indian/Alaska Natives (127), Asian (32), Native Hawaiian/Pacific Islander (9) and others (57). §: Primary care providers include family medicine doctors, internists and/or general paediatricians. Other specialists include cardiologists, pulmonologists, dermatologists, gastroenterologists, neurologists, ophthalmologists, psychiatrists and/or rheumatologists. ƒ: Steroids: prednisone, methylprednisolone and dexamethasone. Cytotoxic agents: hydroxychloroquine, chloroquine, methotrexate, azathioprine, leflunomide, mycophenolate and cyclophosphamide. Tumour necrosis factor inhibitors: infliximab, adalimumab, certolizumab, golimumab and etanercept. Others: rituximab, pentoxifylline, intravenous Ig, thalidomide, adrenocorticotropic hormone.